Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp


Triple Negative Breast Cancer patients – Capivasertib helps you survive

PURPOSE OF THE STUDY The trial was designed to evaluate the safety and efficacy of adding Capivasertib to Taxol as first-line therapy for metastatic TNBC

Read More »

HER2 breast cancer patients! 6% complete remission 54.9% shrinkage with Trastuzumab Deruxtecan, DS-8201

When was it reported? The outcome of the phase II, multicenter, open-label, single-arm DESTINY-Breast trial was reported at the 2019 San Antonio Breast Cancer Symposium,

Read More »

Potential Cure of recurrent GBM with the Oncolytic Herpes Virus G47∆

Interim results The virus has been designated a breakthrough therapy in Japan. An interim analysis of a trial of the oncolytic herpes virus G47∆ has

Read More »

Glioblastoma Moltiforme, GBM – NEW immunotherapies stop from growing in newly diagnosed patients

Background According to interim findings of a phase II trial, the combination of INO-5401, a T-cell–activating immunotherapy and INO-9012, an immune activator of a different

Read More »

To get a personal free assessment to our service please in fill in your details and we will get back to you shortly

Improve therapeutic outcomes, prolong life and quality of life are our main business. We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics

Close Menu